Definition of complete remission in patients with acute myeloid leukaemia (AML) represents a highly heterogeneous state associated with diverse clinical outcomes. The use of minimal residual disease (MRD) as a response criterion allows efficacy assessment of AML therapy. The authors review the characteristics and challenges of the modalities used to detect MRD and outline opportunities to improve clinical use of MRD measurements.
- Christopher S. Hourigan
- Judith E. Karp
